PUBLISHER: The Business Research Company | PRODUCT CODE: 1703142
PUBLISHER: The Business Research Company | PRODUCT CODE: 1703142
Clopidogrel is a medication used to prevent blood clots in conditions such as coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is particularly prescribed to reduce the risk of these events in individuals with acute coronary syndrome, recent heart attack, recent stroke, or a history of peripheral artery disease.
Clopidogrel is available in several formulations, 25mg, 75mg, and 300mg. Clopidogrel 25mg is specifically intended to inhibit blood clot formation and decrease the likelihood of heart attack and stroke. These formulations are distributed through various sales channels including direct sales and indirect sales, and are utilized in diverse settings such as hospitals, private clinics, retail pharmacies, online pharmacies, and others. They are used by a range of end-users including individuals affected by heart attack, strokes, peripheral vascular disease, coronary artery disease, cerebrovascular disease, among others.
The clopidogrel market research report is one of a series of new reports from The Business Research Company that provides clopidogrel market statistics, including clopidogrel industry global market size, regional shares, competitors with a clopidogrel market share, detailed clopidogrel market segments, market trends and opportunities, and any further data you may need to thrive in the clopidogrel industry. This clopidogrel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The clopidogrel market size has grown rapidly in recent years. It will grow from $11.87 billion in 2024 to $13.16 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increased use of generic products, government initiatives for healthcare, increased use of clopidogrel in hospitals, increased use of clopidogrel in retail pharmacies, increased use of clopidogrel in emerging markets.
The clopidogrel market size is expected to see rapid growth in the next few years. It will grow to $19.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to rise in geriatric population, increasing awareness of cardiovascular health, growing healthcare expenditure, increasing focus on cardiovascular health, growing demand for effective cardiovascular treatments. Major trends in the forecast period include advancements in new technology, demand for cardiovascular medications, advancements in medical research, demand for antiplatelet medications, use of clopidogrel in combination with aspirin.
The growing prevalence of cardiovascular diseases is expected to drive the expansion of the clopidogrel market. Cardiovascular diseases encompass a variety of conditions that affect the heart's structure or function, leading to reduced blood flow, abnormal heart rhythms, and other complications. The rise in cardiovascular diseases is attributed to factors such as population growth and aging, lifestyle choices, stress, inactivity, challenges within healthcare systems, and genetic and environmental influences. Clopidogrel helps prevent cardiovascular issues by inhibiting platelet aggregation, thus reducing the risk of clot formation. It is especially effective in managing acute coronary syndromes, post-PCI care, stroke prevention, and peripheral arterial disease. For example, in August 2022, the American College of Cardiology, a US-based non-profit medical association, published a report predicting an increase in all four major cardiovascular risk factors in the United States from 2025 to 2060. The most significant rise is expected in diabetes, with a 39.3% increase, reaching 55 million individuals, followed by dyslipidemia (up 27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The report also forecasted substantial increases in cardiovascular disease rates, with the largest expected rises in stroke (33.8% to 15 million), heart failure (33.4% to 13 million), ischemic heart disease (30.7% to 29 million), and heart attacks (16.9% to 16 million). As a result, the increasing burden of cardiovascular diseases is fueling the growth of the clopidogrel market.
The growing aging population is expected to drive the growth of the clopidogrel market. An aging population refers to a demographic shift in which the proportion of elderly individuals, typically aged 65 and older, increases due to higher life expectancy and declining birth rates. This trend is primarily fueled by advancements in healthcare and longer life spans. Clopidogrel is essential for the aging population to prevent blood clots and reduce the risk of heart attacks, strokes, and other cardiovascular events, which are more common in older individuals. For example, in October 2022, the World Health Organization (WHO), a Switzerland-based agency responsible for global public health, reported that by 2030, one in six people worldwide is expected to be 60 or older. By 2050, the global population of individuals aged 60 and above is projected to reach 2.1 billion. As a result, the increasing number of elderly individuals is driving the growth of the clopidogrel market.
In March 2023, Adragos Pharma GmbH, a Germany-based contract development and manufacturing organization (CDMO), acquired Sanofi's leading pharmaceutical manufacturing facilities in Japan for an undisclosed amount. This acquisition positioned Adragos Pharma as the third-largest pure-play contract manufacturer in Japan, a key market for the company. The deal also established a long-term supply agreement between Adragos Pharma and Sanofi. Sanofi, a France-based manufacturer, is known for producing clopidogrel.
Major companies operating in the clopidogrel market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca Plc, Bristol-Myers Squibb, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly & Company, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals GmbH, Cipla Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals, Zydus Cadila Healthcare Ltd., Alkem Laboratories Ltd.
North America was the largest region in the clopidogrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clopidogrel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the clopidogrel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The clopidogrel market consists sales of plavix, act clopidogrel, clopido grel, clopidogrel tablet and accel-clopidogrel. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Clopidogrel Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on clopidogrel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for clopidogrel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clopidogrel market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.